FilingSEC EDGAR8-K
Tenaya Therapeutics Receives FDA RMAT Designation for TN-401
· SEC accepted
Stageclinical
Filing content
The company received FDA RMAT designation for its TN-401 gene therapy and confirmed that current cash resources are sufficient to fund operations into the fourth quarter of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…